You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Eyal Lebel -- 2128 2022-04-13 17:30:42 |
2 format correct Catherine Yang + 2 word(s) 2130 2022-04-14 03:23:05 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Lebel, E.; Nachmias, B.; Pick, M.; Gross Even Zohar, N.; Gatt, M. Surface Antigens in Multiple Myeloma. Encyclopedia. Available online: https://encyclopedia.pub/entry/21728 (accessed on 05 December 2025).
Lebel E, Nachmias B, Pick M, Gross Even Zohar N, Gatt M. Surface Antigens in Multiple Myeloma. Encyclopedia. Available at: https://encyclopedia.pub/entry/21728. Accessed December 05, 2025.
Lebel, Eyal, Boaz Nachmias, Marjorie Pick, Noa Gross Even Zohar, Moshe Gatt. "Surface Antigens in Multiple Myeloma" Encyclopedia, https://encyclopedia.pub/entry/21728 (accessed December 05, 2025).
Lebel, E., Nachmias, B., Pick, M., Gross Even Zohar, N., & Gatt, M. (2022, April 13). Surface Antigens in Multiple Myeloma. In Encyclopedia. https://encyclopedia.pub/entry/21728
Lebel, Eyal, et al. "Surface Antigens in Multiple Myeloma." Encyclopedia. Web. 13 April, 2022.
Surface Antigens in Multiple Myeloma
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11071809

Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to the bone marrow matrix and stromal cells, while others are involved in intercellular interactions that result in differentiation of B-cells to plasma cells (PC). These interactions are also involved in malignant transformation of the normal PC to MM PC as well as disease progression.

surface antigens multiple myeloma

1. Introduction

Multiple myeloma (MM) is a neoplastic disease of plasma cells (PC) causing painful destructive bony lesions, anemia, hypercalcemia, kidney injury, and immune dysfunction [1]. The disease is precedented by monoclonal gammopathy of unknown significance (MGUS), a very common pre-malignant condition, characterized by a small PC clone secreting a monoclonal protein [1][2]. Though many of the abnormal properties of the PC including major chromosomal events are already present at the MGUS state, additional molecular events are needed for progression from MGUS to MM, and only a minority of MGUS patients will eventually progress to MM [1][2]. Great efforts have been undertaken to understand the pathogenesis of the evolution from a normal PC to MGUS and then MM and to understand the mechanism of MM PC survival, proliferation, and resistance to therapies [3][4][5][6][7].

2. Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

  • # CD38
CD38 is a surface protein which is expressed at high levels on normal and malignant PC as compared with the rest of the BM [8]. Consequently, it is utilized mostly for identification of PC, and not for discrimination between normal and malignant PC, although malignant cells can express a lower level of CD38 than normal PCs. CD38 expression is common to all hematopoietic cells but its levels are usually lower in mature myeloid cells and lymphoid lineage cells and negative on red cells and platelets. Activated hematopoietic cells upregulate CD38 expression to high levels, although not as high as PC [9]. This upregulation is due to binding to CD31 (present on the endothelium) and/or hyaluronan, which mediates CD38 adhesion to the BM ECM [8][10]. In addition, CD38 has an enzymatic activity: it can catalyze the generation of potent messengers that regulate intracellular calcium levels [11], which overall promotes proliferation.  CD38-dependent adenosin production causes immune suppression.
Daratumumab, a full humanized anti-CD38 antibody, was the first anti-CD38 therapy that was investigated, followed by isatuximab [9][11]. The mechanism of both drugs involves complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), induction of apoptosis, and modulation of CD38 enzyme activities [12]. Both daratumumab and isatuximab have shown unprecedented efficacy, and thus paved their way to act as the backbone of treatment of relapsed and refractory MM, in various combinations. In addition to many other advantages, the rationale for anti-CD38 combinations is the ability of some anti-myeloma therapies to increase the density of CD38 molecules on the MM cells [13].
  • # CD138
CD138 (syndecan-1) is a large glycoprotein expressed on pre-B-cells, lost during B-cell maturation and re-expressed on PC [14], where it is one of the most abundant surface molecules [15]. Consequently, similar to CD38, its role in diagnosis is mainly for the identification of PC and not the discrimination between normal and malignant PC. Carrying heparan sulphate chains, CD138 interacts directly with ECM proteins such as fibronectin, promoting cell adhesion [10]. Moreover, CD138 plays a critical role in the ability of heparan sulphate-binding cytokines and chemokines to interact with the MM cell and promote its proliferation and survival [16].
Recently, CD138high MM cells were characterized by a proliferative but static phenotype, as opposed to CD138low MM cells which were more motile and disseminative [15]. Junctional Adhesion Molecule-C was described as a key regulator in the switch between these two states [17]. These recent findings may explain earlier reports of CD138 shedding into the plasma [18], and correlating high plasma levels of soluble CD138 with a dismal prognosis [19].
  • # CD45
CD45 expression is ubiquitous on nucleated hematopoietic cells, and is thought to be a regulator of antigen-mediated T- and B-lymphocyte activation [20][21]. In normal BM, there appears to be a balance between the number of early PC, that express CD45, and terminally differentiated PC, that are CD45-negative [20]. In MM, the PC population is skewed toward CD45+ cells, that appear to be more proliferative compared to CD45− cells, co-express other different surface molecules, and respond differently to inhibitory and activating stimuli [20][22][23][24][25][26][27].
In daratumumab-treated patients, an increase in CD45 expression is associated with a very aggressive and resistant disease [28]. A small clone expressing high levels of CD45 may imply the existence of MRD that at relapse will become aggressive. In contrast, others reported worse prognosis in CD45− disease [29].
  • # CD19
CD19 is a B-lineage lymphocyte antigen expressed on the surface of most B-cells. Its expression appears during immunoglobulin gene rearrangement, which coincides with B-lineage commitment at the hematopoietic stem cell stage and its expression progressively increases in concentration along B-cell maturation and terminal differentiation to PC. Throughout development, the surface density of CD19 is highly regulated, with the more mature B-cells expressing higher levels of CD19 [30].
CD19 has a dual role. The first role is as part of the B-cell receptor (BCR) complex, allowing B-cell differentiation and the antigen-dependent maturation processes, which the cell survival is dependent on [31][32]. In the second role, it interacts with CD21 to activate the BCR, and is essential for B-cell functionality by decreasing the threshold of the BCR activation [33]. It also interacts with other ligands such as complement (C3d) receptor, CD81, and CD225 [30][34].
CD19 has been utilized as a target for B-cell leukemia immunotherapies with antibodies or bi-specific antibodies, and as the main antigen used for chimeric antigen receptors (CAR)-T-cell therapy in B-cell lymphoma treatment [35][36]. The latter modality has been tested in MM patients based on the MM stem cell theory. A published case report described a deep response to CD19 CAR-T in MM patients, despite the absence of CD19 expression in 99.95% of the patient’s neoplastic PC [37]. This led to a recently reported exploration of autologous transplantation followed by CD19 CAR-T-cell therapy in MM patients [38], and moreover to the future construction of a dual anti-BCMA and anti-CD19 CAR-T strategy [39].
  • # CD117
CD117 (c-kit) is a tyrosine kinase receptor involved in cell differentiation and proliferation [40][41]. It is essential for the survival of CD34+ myeloid precursors, and is also strongly expressed on mast cells and some sub-populations of natural killer (NK) cells and early T-cell precursors [42]. Some cancers are also characterized by CD117 expression, including gastrointestinal stromal tumor (GIST) and lymphoproliferative and myeloproliferative neoplasms [40][42].
About a third of MM PC express CD117, as opposed to almost none of normal PC [42][43]. Interestingly, it was found that CD117 expression is frequently lost at disease relapse [40]. Similar to other malignancies, following activation by its ligand stem cell factor (SCF), CD117 promotes cell proliferation in MM [40]. Compared to CD117−, CD117+ MM patients were found to have more hyper-diploid karyotype cases, less 14 chromosome translocations, and overall, a better prognosis [40][42][43][44][45], but not in all reports [46]. C-kit inhibition was not successful as a treatment for MM [47].
  • # CD56
CD56, or neural cell adhesion molecule (NCAM), is a membrane glycoprotein and is a member of the immunoglobulin superfamily. CD56 is expressed on neural cells, muscle tissues, and various lymphoid cells. It is expressed on a small percent of normal PC but overexpressed in about 65–80% of malignant PC dyscrasias, especially MM [48][49][50]. Overexpression of CD56 promotes the transcription of CREB1 targets, the anti-apoptotic genes BCL2 and MCL1, resulting in a robust anti-apoptotic effect [51].
CD56 positivity in MM correlates with greater osteolytic burden, and is associated with well-differentiated neoplastic PC and a lower frequency of standard risk features, such as the presence of t(11;14) [51]. In another study, CD56 absence was associated with unfavorable prognostic parameters, such as elevated lactate dehydrogenase (LDH) and β2-microglobulin levels, advanced stage, and BM plasmacytosis of above 60%, however none of these factors effected patients’ OS [52]. Others have shown that CD56 absence may be associated with extramedullary involvement, plasma-blastic morphology, a plasma cell leukemia (PCL) state, non-hyper-diploid chromosomal abnormalities, and eventually worse PFS [40][53][54][55]. Okura et al. also reported on worse OS for CD56-negative MM [56]. In conclusion, CD56 may indeed be associated with prognosis and remains as one of the leading MM markers [57].
  • # CD81
CD81 is a transmembrane protein of the tetraspanin family, which is expressed on normal B-cells and plays a critical role in the regulation of B-cell receptor activation [58], and as mentioned before, trafficking and expression of CD19 [59][60][61]. In vitro studies identified an anti-tumorigenic effect of CD81 in MM cells, including reduced proliferation and invasion potential [62], as well as enhanced protein synthesis with activation of unfolded protein response (UPR) [63], causing autophagic MM cell death. CD81 has a bright expression on normal PC, and is usually dim on abnormal PC, with up to a 40–45% detection rate in MM [64][65]. Paiva et al. of the PETHEMA group reported on a cohort of 233 newly diagnosed MM patients, with CD81+ MM patients having a significantly shorter PFS (3-year rates of 26% vs. 52%, in CD81+ vs. CD81−, respectively), which translated to a significantly shorter OS [64]. This group further showed, in a larger cohort, that MM cases expressing the combination of CD38low, CD81+, and CD117− had the strongest correlation with an inferior outcome [66]. The significance of the CD81+ and CD117− expression pattern as a strong adverse prognostic marker was further reported by Chen et al. [43]. CD81 expression in smoldering MM (SMM) is correlated with shorter time to progression to active MM [64]. CD81 was also demonstrated as one of the most useful markers to detect different sub-clones. Interestingly, progression from MGUS to MM is characterized by reduced sub-clones’ variability with the appearance of a dominant clone. The immunophenotype profile was similar between MGUS and MM, however loss of CD27 and an increase in CD81 was noted in the dominant clone of relapsed patients [67].
  • # CD27
CD27 is a membrane glycoprotein of the tumor necrosis factor (TNF) superfamily, which is expressed on the surface of most peripheral T-cells and certain sub-populations of B-cells [68], specifically memory B-cells and PC [69]. CD27 expression on T-cells acts as a co-stimulatory receptor, while binding of CD70 to CD27 on B-cells promotes differentiation to PC [70]. Several studies have shown that loss of CD27 expression characterizes progression to MM and less favorable prognosis [67][71][72]. Chu et al. investigated the significance of CD27 expression in newly diagnosed MM patients and found that CD27-negative disease had higher adverse risk characteristics, including higher PC burden and advanced stage. Furthermore, PFS was significantly shorter in the CD27-negative group [73]. Counterintuitively, the tumor cells in PCL displayed a high expression of CD27, which was shown to be protective of dexamethasone-induced apoptosis [74]. The difference between MM and PCL regarding CD27 expression is still not well understood.
  • # CD28
CD28 is expressed on T-cells and acts as a co-stimulatory receptor with the T-cell receptor, resulting in enhanced proliferation and cytokine secretion [75][76]. CD28 expression is highly specific for MM PC, as it is not expressed on normal PC. Moreover, CD28 expression is correlated with disease progression, reaching up to 93% and 100% expression on relapsed extra-medullary MM and PCL, respectively [77]. T-cell activation is mediated by the binding of CD80 and CD86, expressed on antigen-presenting cells, to CD28 on MM PC. Data suggests that CD80/86 binding to CD28 on MM PCs generates a crosstalk between the stromal and MM PC. This promotes secretion of IL-6 by the stromal cells, which in turn supports survival of MM cells and ameliorates the anti-proliferative effects of dexamethasone [78]. In addition, activation of CD28 also induces activation of PI3 kinase signaling in MM PC, with downstream nuclear factor kappa B (NFkB) activation causing a pro-survival effect, which further strengthens the role of CD28 in the stroma–myeloma cell interaction [79].
  • # CD24
CD24 is a highly glycosylated protein expressed on the surface of most B-lymphocytes, neutrophils, and its precursor myelocytes and differentiating neuroblasts. CD24 is expressed on pre-B-lymphocytes, remains expressed on mature resting B-cells, and becomes downregulated during the maturation process to PC [80][81]. A lack of CD24 results in a decrease in maturation of B-cells in mice [82]. CD24 overexpression has been found in many solid cancers and has been correlated with worse prognosis and presence of metastasis [83][84][85]. In MM PC, CD24 mRNA has been shown to be downregulated, correlated to worse OS [86]. The decreased tumorigenicity correlated with a “more normal” PC immunophenotype in patients with MM and correlated with CD45 expression [87]. Furthermore, following immunophenotype analysis in 124 MM patients treated with bortezomib, cyclophosphamide, and dexamethasone, the researchers found that elevated CD24 expression on PC at diagnosis correlated significantly with longer PFS and OS (Gross Even-Zohar N, et al., submitted). Indeed, among CD19, CD45, CD117, CD56, and CD24, the latter was the only marker that retained its prognostic impact on PFS and OS. In light of these results, the researchers believe that the addition of CD24 to the immunophenotype panel of MM at diagnosis should be considered. Its expression during the course of the disease is being studied.

References

  1. van de Donk, N.W.C.J.; Pawlyn, C.; Yong, K.L. Multiple myeloma. Lancet 2021, 397, 410–427.
  2. Kumar, S.K.; Rajkumar, V.; Kyle, R.A.; Van Duin, M.; Sonneveld, P.; Mateos, M.-V.; Gay, F.; Anderson, K.C. Multiple myeloma. Nat. Rev. Dis. Prim. 2017, 3, 17046.
  3. Díaz-Tejedor, A.; Lorenzo-Mohamed, M.; Puig, N.; García-Sanz, R.; Mateos, M.-V.; Garayoa, M.; Paíno, T. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers 2021, 13, 1353.
  4. García-Ortiz, A.; Rodríguez-García, Y.; Encinas, J.; Maroto-Martín, E.; Castellano, E.; Teixidó, J.; Martínez-López, J. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers 2021, 13, 217.
  5. Jang, J.S.; Li, Y.; Mitra, A.; Bi, L.; Abyzov, A.; Van Wijnen, A.J.; Baughn, L.B.; Van Ness, B.; Rajkumar, V.; Kumar, S.; et al. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019, 9, 2.
  6. Mahindra, A.; Hideshima, T.; Anderson, K.C. Multiple myeloma: Biology of the disease. Blood Rev. 2010, 24 (Suppl. 1), S5–S11.
  7. Pinto, V.; Bergantim, R.; Caires, H.R.; Seca, H.; Guimarães, J.E.; Vasconcelos, M.H. Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers 2020, 12, 407.
  8. Deaglio, S.; Mehta, K.; Malavasi, F. Human CD38: A (r)evolutionary story of enzymes and receptors. Leuk. Res. 2001, 25, 1–12.
  9. Van De Donk, N.W.C.J.; Janmaat, M.L.; Mutis, T.; Lammerts Van Bueren, J.J.; Ahmadi, T.; Sasser, A.K.; Lokhorst, H.M.; Parren, P.W.H.I. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond. Immunol. Rev. 2016, 270, 95–112.
  10. Katz, B.-Z. Adhesion molecules—The lifelines of multiple myeloma cells. Semin. Cancer Biol. 2010, 20, 186–195.
  11. Van De Donk, N.W.; Usmani, S.Z. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front. Immunol. 2018, 9, 2134.
  12. Nooka, A.K.; Kaufman, J.; Hofmeister, C.C.; Joseph, N.S.; Heffner, T.L.; Gupta, V.A.; Sullivan, H.C.; Neish, A.S.; Dhodapkar, M.V.; Lonial, S. Daratumumab in multiple myeloma. Cancer 2019, 125, 2364–2382.
  13. Costa, F.; Palma, B.D.; Giuliani, N. CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells 2019, 8, 1632.
  14. Sanderson, R.; Børset, M. Syndecan-1 in B lymphoid malignancies. Ann. Hematol. 2002, 81, 125–135.
  15. Akhmetzyanova, I.; McCarron, M.J.; Parekh, S.; Chesi, M.; Bergsagel, P.L.; Fooksman, D.R. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 2020, 34, 245–256.
  16. Ren, Z.; Spaargaren, M.; Pals, S.T. Syndecan-1 and stromal heparan sulfate proteoglycans: Key moderators of plasma cell biology and myeloma pathogenesis. Blood 2021, 137, 1713–1718.
  17. Brandl, A.; Solimando, A.; Mokhtari, Z.; Tabares, P.; Medler, J.; Manz, H.; Da Vià, M.C.; Croci, G.A.; Kurzwart, M.; Thusek, S.; et al. Junctional Adhesion Molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans. Blood Adv. 2021, in press.
  18. Purushothaman, A.; Uyama, T.; Kobayashi, F.; Yamada, S.; Sugahara, K.; Rapraeger, A.C.; Sanderson, R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115, 2449–2457.
  19. Seidel, C.; Sundan, A.; Hjorth, M.; Turesson, I.; Dahl, I.M.S.; Abildgaard, N.; Waage, A.; Børset, M. Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 2000, 95, 388–392.
  20. Kumar, S.; Rajkumar, S.V.; Kimlinger, T.; Greipp, P.R.; E Witzig, T. CD45 expression by bone marrow plasma cells in multiple myeloma: Clinical and biological correlations. Leukemia 2005, 19, 1466–1470.
  21. Trowbridge, I.S.; Thomas, M.L. CD45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and Development. Annu. Rev. Immunol. 1994, 12, 85–116.
  22. Kimlimger, T.K.; Timm, M.M.; Rajkumar, S.V.; Haug, J.L.; Kline, M.P.; Witzig, T.E.; Kumar, S. Phenotypic Characterization of the CD45+ and CD45− Plasma Cell Compartments in Monoclonal Gammopathies. Blood 2006, 108, 3505.
  23. Man, W.Y.; Khong, T.; Spencer, A. CRISPR-Cas9 Mediated CD45 Knockout Inactivates Src Family Kinases and Impairs Cell Migration in Multiple Myeloma. Blood 2018, 132 (Suppl. 1), 1907.
  24. Liu, S.; Ishikawa, H.; Tsuyama, N.; Abroun, S.; Li, F.-J.; Otsuyama, K.-I.; Zheng, X.; Ma, Z.; Maki, Y.; Obata, M.; et al. CD45 Defines Signaling Thresholds Critical for Proliferation and Apoptosis in Myeloma Cells. Blood 2004, 104, 3345.
  25. Pellat-Deceunynck, C.; Robillard, N.; Bataille, R. The Coexpression of CD11a and CD45bright Is the Hallmark of Proliferating Myeloma Cells. Blood 2004, 104, 3347.
  26. Descamps, G.; Wuillème-Toumi, S.; Trichet, V.; Venot, C.; Debussche, L.; Hercend, T.; Collette, M.; Robillard, N.; Bataille, R.; Amiot, M. CD45negbut Not CD45posHuman Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642. J. Immunol. 2006, 177, 4218–4223.
  27. Pellat-Deceunynck, C.; Bataille, R. Normal and malignant human plasma cells: Proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol. Dis. 2004, 32, 293–301.
  28. Pick, M.; Vainstein, V.; Goldschmidt, N.; Lavie, D.; Libster, D.; Gural, A.; Grisariu, S.; Avni, B.; Ben Yehuda, D.; Gatt, M.E. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur. J. Haematol. 2018, 100, 494–501.
  29. Moreau, P.; Robillard, N.; Avet-Loiseau, H.; Pineau, D.; Morineau, N.; Milpied, N.; Harousseau, J.-L.; Bataille, R. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004, 89, 547–551.
  30. Wang, K.; Wei, G.; Liu, D. CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 2012, 1, 36.
  31. Haas, K.M.; Tedder, T.F. Role of the CD19 and CD21/35 Receptor Complex in Innate Immunity, Host Defense and Autoimmunity. Adv. Exp. Med. Biol. 2005, 560, 125–139.
  32. Otero, D.C.; Anzelon, A.N.; Rickert, R.C. CD19 Function in Early and Late B Cell Development: I. Maintenance of Follicular and Marginal Zone B Cells Requires CD19-Dependent Survival Signals. J. Immunol. 2003, 170, 73–83.
  33. Sato, S. CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J. Dermatol. Sci. 1999, 22, 1–10.
  34. Chung, E.Y.; Psathas, J.N.; Yu, D.; Li, Y.; Weiss, M.; Thomas-Tikhonenko, A. CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis. J. Clin. Investig. 2012, 122, 2257–2266.
  35. Johnson, P.C.; Abramson, J.S. Engineered T Cells: CAR T Cell Therapy and Beyond. Curr. Oncol. Rep. 2022, 24, 23–31.
  36. Zinzani, P.L.; Minotti, G. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: A narrative review with focus on diffuse large B-cell lymphoma. J. Cancer Res. Clin. Oncol. 2022, 148, 177–190.
  37. Garfall, A.; Maus, M.; Hwang, W.-T.; Lacey, S.F.; Mahnke, Y.; Melenhorst, J.J.; Zheng, Z.; Vogl, D.T.; Cohen, A.; Weiss, B.M.; et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N. Engl. J. Med. 2015, 373, 1040–1047.
  38. Garfall, A.L.; Stadtmauer, E.A.; Hwang, W.-T.; Lacey, S.F.; Melenhorst, J.J.; Krevvata, M.; Carroll, M.P.; Matsui, W.H.; Wang, Q.; Dhodapkar, M.V.; et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 2019, 3, e120505.
  39. Mohyuddin, G.R.; Rooney, A.; Balmaceda, N.; Aziz, M.; Sborov, D.W.; McClune, B.; Kumar, S.K. Chimeric antigen receptor T-cell therapy in multiple myeloma: A systematic review and meta-analysis of 950 patients. Blood Adv. 2021, 5, 1097–1101.
  40. Kraj, M.; Pogłód, R.; Kopeć-Szlęzak, J.; Sokołowska, U.; Woźniak, J.; Kruk, B. C-kit Receptor (CD117) Expression on Plasma Cells in Monoclonal Gammopathies. Leuk. Lymphoma 2004, 45, 2281–2289.
  41. Ocqueteau, M.; Orfao, A.; García-Sanz, R.; Almeida, J.; Gonzalez, M.; Miguel, J.F.S. Expression of the CD117 antigen (C-Kit) on normal and myelomatous plasma cells. Br. J. Haematol. 1996, 95, 489–493.
  42. Bataille, R.; Pellat-Deceunynck, C.; Robillard, N.; Avet-Loiseau, H.; Harousseau, J.-L.; Moreau, P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk. Res. 2008, 32, 379–382.
  43. Chen, F.; Hu, Y.; Wang, X.; Fu, S.; Liu, Z.; Zhang, J. Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis. Cancer Med. 2018, 7, 5920–5927.
  44. Pan, Y.; Wang, H.; Tao, Q.; Zhang, C.; Yang, D.; Qin, H.; Xiong, S.; Tao, L.; Wu, F.; Zhang, J.; et al. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk. Res. 2016, 40, 77–82.
  45. Schmidt-Hieber, M.; Perez-Andres, M.; Paiva, B.; Flores-Montero, J.; Perez, J.J.; Gutierrez, N.C.; Vidriales, M.-B.; Matarraz, S.; Miguel, J.F.S.; Orfao, A. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011, 96, 328–332.
  46. Wang, H.; Zhou, X.; Zhu, J.; Ye, J.; Guo, H.; Sun, C. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncol. Lett. 2018, 16, 5655–5666.
  47. Dispenzieri, A.; Gertz, M.A.; Lacy, M.Q.; Geyer, S.M.; Greipp, P.R.; Rajkumar, S.V.; Kimlinger, T.; Lust, J.A.; Fonseca, R.; Allred, J.; et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk. Lymphoma 2006, 47, 39–42.
  48. Van Camp, B.; Durie, B.; Spier, C.; De Waele, M.; Van Riet, I.; Vela, E.; Frutiger, Y.; Richter, L.; Grogan, T. Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19). Blood 1990, 76, 377–382.
  49. Kraj, M.; Sokołowska, U.; Kopeć-Szlęzak, J.; Pogłód, R.; Kruk, B.; Woźniak, J.; Szpila, T. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk. Lymphoma 2008, 49, 298–305.
  50. Flores-Montero, J.; De Tute, R.; Paiva, B.D.L.; Perez, J.J.; Böttcher, S.; Wind, H.; Sanoja, L.; Puig, N.; Lecrevisse, Q.; Vidriales, M.-B.; et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytom. Part B Clin. Cytom. 2015, 90, 61–72.
  51. Cottini, F.; Rodriguez, J.; Birmingham, M.; Hughes, T.; Sharma, N.; Lozanski, G.; Liu, B.; Yang, Y.; Cocucci, E.; Benson, D.M. CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies. Blood 2021, 138 (Suppl. 1), 889.
  52. Koumpis, E.; Tassi, I.; Malea, T.; Papathanasiou, K.; Papakonstantinou, I.; Serpanou, A.; Tsolas, E.; Kapsali, E.; Vassilakopoulos, T.P.; Papoudou-Bai, A.; et al. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. Pathol.-Res. Pract. 2021, 225, 153567.
  53. Deceunynck, C.; Barille-Nion, S.; Jego, G.; Puthier, D.; Robillard, N.; Pineau, D.; Rapp, M.-J.; Harousseau, J.-L.; Amiot, M.; Bataille, R. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998, 12, 1977–1982.
  54. Miyazaki, K.; Suzuki, K. CD56 for Multiple Myeloma: Lack of CD56 May Be Associated with Worse Prognosis. Acta Haematol. 2018, 140, 40–41.
  55. Škerget, M.; Skopec, B.; Zadnik, V.; Žontar, D.; Podgornik, H.; Reberšek, K.; Furlan, T.; Cernelc, P. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction. Acta Haematol. 2018, 139, 228–234.
  56. Okura, M.; Ida, N.; Yamauchi, T. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Med. Oncol. 2020, 37, 103.
  57. ElMenshawy, N.; Farag, N.A.; Atia, D.M.; Abousamra, N.; Shahin, D.; Fawzi, E.; Ghazi, H.; El-Kott, A.F.; Eissa, M. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients. Cancer Investig. 2021, 39, 777–782.
  58. Carter, R.; Barrington, R. Signaling by the CD19/CD21 Complex on B Cells. Curr. Dir. Autoimmun. 2004, 7, 4–32.
  59. Shoham, T.; Rajapaksa, R.; Kuo, C.-C.; Haimovich, J.; Levy, S. Building of the Tetraspanin Web: Distinct Structural Domains of CD81 Function in Different Cellular Compartments. Mol. Cell. Biol. 2006, 26, 1373–1385.
  60. Shoham, T.; Rajapaksa, R.; Boucheix, C.; Rubinstein, E.; Poe, J.C.; Tedder, T.F.; Levy, S. The Tetraspanin CD81 Regulates the Expression of CD19 During B Cell Development in a Postendoplasmic Reticulum Compartment. J. Immunol. 2003, 171, 4062–4072.
  61. Susa, K.J.; Seegar, T.C.; Blacklow, S.C.; Kruse, A.C. A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking. eLife 2020, 9, e52337.
  62. Tohami, T.; Drucker, L.; Shapiro, H.; Radnay, J.; Lishner, M. Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J. 2007, 21, 691–699.
  63. Zismanov, V.; Drucker, L.; Attar-Schneider, O.; Matalon, S.T.; Pasmanik-Chor, M.; Lishner, M. Tetraspanins stimulate protein synthesis in myeloma cell lines. J. Cell. Biochem. 2012, 113, 2500–2510.
  64. Paiva, B.; Gutiérrez, N.-C.; Chen, X.; Vídriales, M.-B.; Montalbán, M.Á.; Rosiñol, L.; Oriol, A.; Martínez-López, J.; Mateos, M.-V.; López-Corral, L.; et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012, 26, 1862–1869.
  65. Tembhare, P.R.; Yuan, C.M.; Venzon, D.; Braylan, R.; Korde, N.; Manasanch, E.; Zuchlinsky, D.; Calvo, K.; Kurlander, R.; Bhutani, M.; et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk. Res. 2014, 38, 371–376.
  66. Arana, P.; Paiva, B.; Cedena, M.-T.; Puig, N.; Cordon, L.; Vidriales, M.-B.; Gutierrez, N.C.; Chiodi, F.; Burgos, L.; Anglada, L.-L.; et al. Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 2018, 32, 971–978.
  67. Tarín, F.; López-Castaño, F.; García-Hernández, C.; Beneit, P.; Sarmiento, H.; Manresa, P.; Alda, O.; Villarrubia, B.; Blanes, M.; Bernabéu, J.; et al. Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Acta Haematol. 2019, 141, 1–6.
  68. Maurer, D.; Holter, W.; Majdic, O.; Fischer, G.F.; Knapp, W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur. J. Immunol. 1990, 20, 2679–2684.
  69. Jung, J.; Choe, J.; Mustelin, T.; Choi, Y.S. Regulation of CD27 expression in the course of germinal center B cell differentiation: The pivotal role of IL-10. Eur. J. Immunol. 2000, 30, 2437–2443.
  70. Agematsu, K.; Nagumo, H.; Oguchi, Y.; Nakazawa, T.; Fukushima, K.; Yasui, K.; Ito, S.; Kobata, T.; Morimoto, C.; Komiyama, A. Generation of plasma cells from peripheral blood memory B cells: Synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998, 91, 173–180.
  71. Katayama, Y.; Sakai, A.; Oue, N.; Asaoku, H.; Otsuki, T.; Shiomomura, T.; Masuda, R.; Hino, N.; Takimoto, Y.; Imanaka, F.; et al. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br. J. Haematol. 2003, 120, 223–234.
  72. Guikema, J.E.J.; Hovenga, S.; Vellenga, E.; Conradie, J.J.; Abdulahad, W.H.; Bekkema, R.; Smit, J.W.; Zhan, F.; Shaughnessy, J., Jr.; Bos, N.A. CD27 is heterogeneously expressed in multiple myeloma: Low CD27 expression in patients with high-risk disease. Br. J. Haematol. 2003, 121, 36–43.
  73. Chu, B.; Bao, L.; Wang, Y.; Lu, M.; Shi, L.; Gao, S.; Fang, L.; Xiang, Q.; Liu, X. CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma. Clin. Immunol. 2020, 213, 108363.
  74. Guikema, J.E.J.; Vellenga, E.; Abdulahad, W.H.; Hovenga, S.; Bos, N.A. CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases. Br. J. Haematol. 2004, 124, 299–308.
  75. Harding, F.A.; McArthur, J.G.; Gross, J.A.; Raulet, D.; Allison, J. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356, 607–609.
  76. Borowski, A.B.; Boesteanu, A.C.; Mueller, Y.M.; Carafides, C.; Topham, D.J.; Altman, J.D.; Jennings, S.R.; Katsikis, P.D. Memory CD8+ T cells require CD28 costimulation. J. Immunol. 2007, 179, 6494–6503.
  77. Robillard, N.; Jego, G.; Pellat-Deceunynck, C.; Pineau, D.; Puthier, D.; Mellerin, M.P.; Barillé, S.; Rapp, M.J.; Harousseau, J.L.; Amiot, M.; et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin. Cancer Res. 1998, 4, 1521–1526.
  78. Nair, J.R.; Carlson, L.M.; Koorella, C.; Rozanski, C.H.; Byrne, G.E.; Bergsagel, P.L.; Shaughnessy, J.P.; Boise, L.H.; Chanan-Khan, A.; Lee, K.P. CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment. J. Immunol. 2011, 187, 1243–1253.
  79. Bahlis, N.J.; King, A.M.; Kolonias, D.; Carlson, L.M.; Liu, H.Y.; Hussein, M.A.; Terebelo, H.R.; Byrne, G.E.; Levine, B.L.; Boise, L.H.; et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007, 109, 5002–5010.
  80. Hunte, B.E.; Capone, M.; Zlotnik, A.; Rennick, D.; Moore, T.A. Acquisition of CD24 expression by Lin-CD43+B220(low)ckit(hi) cells coincides with commitment to the B cell lineage. Eur. J. Immunol. 1998, 28, 3850–3856.
  81. Kristiansen, G.; Sammar, M.; Altevogt, P. Tumour Biological Aspects of CD24, a Mucin-Like Adhesion Molecule. J. Mol. Histol. 2004, 35, 255–262.
  82. Wenger, R.H.; Kopf, M.; Nitschke, L.; Lamers, M.C.; Köhler, G.; Nielsen, P.J. B-cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24). Transgenic Res. 1995, 4, 173–183.
  83. Kristiansen, G.; Pilarsky, C.; Pervan, J.; Stürzebecher, B.; Stephan, C.; Jung, K.; Loening, S.; Rosenthal, A.; Dietel, M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58, 183–192.
  84. Kristiansen, G.; Winzer, K.-J.; Mayordomo, E.; Bellach, J.; Schlüns, K.; Denkert, C.; Dahl, E.; Pilarsky, C.; Altevogt, P.; Guski, H.; et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 2003, 9, 4906–4913.
  85. Kristiansen, G.; Schlüns, K.; Yongwei, Y.; Denkert, C.; Dietel, M.; Petersen, I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer 2003, 88, 231–236.
  86. Alaterre, E.; Raimbault, S.; Goldschmidt, H.; Bouhya, S.; Requirand, G.; Robert, N.; Boireau, S.; Seckinger, A.; Hose, D.; Klein, B.; et al. CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma. Oncotarget 2017, 8, 98931–98944.
  87. Gilad, N.; Zukerman, H.; Pick, M.; Gatt, M.E. The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression. Oncotarget 2019, 10, 5480–5491.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Hematology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Eyal Lebel , Boaz Nachmias , Marjorie Pick , Noa Gross Even Zohar , Moshe Gatt
View Times: 903
Revisions: 2 times (View History)
Update Date: 14 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback